Cover Image
市場調查報告書

EpiCast Report:庫欣氏症候群(CS)的流行病學預測

EpiCast Report: Cushing's Syndrome - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 317759
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:庫欣氏症候群(CS)的流行病學預測 EpiCast Report: Cushing's Syndrome - Epidemiology Forecast to 2023
出版日期: 2014年12月01日 內容資訊: 英文 62 Pages
簡介

庫欣氏症候群(CS),糖皮質素(皮質醇等)分泌過剩而引起,稀少的疾病。全球主要6個國家美國、法國、德國、義大利、西班牙、英國)確診庫欣氏症候群(CS)的患者數,從2013年的32,634人,預計今後10年增加0.59%到34,573人。

本報告提供全球主要6個國家的庫欣氏症候群(CS)調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:患者數
    • 預測的前提條件與手法:即時TSS轉換期
  • 庫欣氏症候群的流行病學預測
    • 庫欣氏症候群(CS)
    • 庫欣病
    • 異所性ACTH CS
    • 腎上腺腺瘤CS
    • 腎上腺癌症CS
    • 確診的總患者數(年齡標準化)
    • 即時TSS轉換期
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER084-14

Cushing's syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, such as cortisol. Cortisol is a hormone produced by the adrenal glands that has many functions in the body, such as anti-inflammatory action, antiallergic action, antianabolic action, and amino acid catabolic action. CS is associated with increased mortality caused by complications due to excess cortisol.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of CS in the 6MM, from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed prevalent cases in 2023, at an annual growth rate of 0.59% in the forecast period. In 2023, the US will have the highest number of diagnosed prevalent cases of CS, with 17,162 diagnosed prevalent cases.

For this analysis, GlobalData epidemiologists used data available from the Orphanet database to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Cushing's disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM. The forecast provides the age- and sex-specific diagnosed prevalent cases of CS subtypes in the six markets, providing a comprehensive view of CS. In addition, this analysis provides detailed, clinically relevant segmentations for Cushing's disease in order to improve the management of the disease.

Scope

  • The Cushing's syndrome (CS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing's disease, ectopic- adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to =85 years) and sex in these markets.
  • The CS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global CS market.
  • Quantify patient populations in the global CS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods - Prevalent Cases
    • 3.4.4. Forecast Assumptions and Methods - Immediate TSS Outcomes
  • 3.5. Epidemiological Forecast for Cushing's Syndrome (2013-2023)
    • 3.5.1. Cushing's Syndrome
    • 3.5.2. Cushing's Disease
    • 3.5.3. Ectopic Adrenocorticotropic Hormone Cushing's Syndrome
    • 3.5.4. Adrenal Adenoma Cushing's Syndrome
    • 3.5.5. Adrenal Carcinoma Cushing's Syndrome
    • 3.5.6. Age-Standardized Diagnosed Prevalence Rates
    • 3.5.7. Immediate Transsphenoidal Adenomectomy Surgery Outcomes
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors for Cushing's Syndrome
  • Table 2: 6MM, Sources of CS Prevalence Data
  • Table 3: 6MM, Diagnosed Prevalent Cases of CS, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 4: 6MM, Age-Specific Diagnosed Prevalent Cases of CS, Both Sexes, N (Row %), 2013
  • Table 5: 6MM, Sex-Specific Diagnosed Prevalent Cases of CS, Ages ≥18 Years, N (Row %), 2013
  • Table 6: 6MM, Diagnosed Prevalent Cases of Cushing's Disease, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 7: 6MM, Age-Specific Diagnosed Prevalent Cases of Cushing's Disease, Both Sexes, N (Row %), 2013
  • Table 8: 6MM, Sex-Specific Diagnosed Prevalent Cases of Cushing's Disease, Ages ≥18 Years, N (Row %), 2013
  • Table 9: 6MM, Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 10: 6MM, Age-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Both Sexes, N (Row %), 2013
  • Table 11: 6MM, Sex-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ≥18 Years, N (Row %), 2013
  • Table 12: 6MM, Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 13: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Both Sexes, N (Row %), 2013
  • Table 14: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ≥18 Years, N (Row %), 2013
  • Table 15: 6MM, Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 16: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Both Sexes, N (Row %), 2013
  • Table 17: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ≥18 Years, N (Row %), 2013
  • Table 18: 6MM, Immediate TSS Outcomes, Both Sexes, N, 2013

List of Figures

  • Figure 1: 6MM, Diagnosed Prevalent Cases of CS, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 2: 6MM, Age-Specific Diagnosed Prevalent Cases of CS, Both Sexes, N, 2013
  • Figure 3: 6MM, Sex-Specific Diagnosed Prevalent Cases of CS, Ages ≥18 Years, N, 2013
  • Figure 4: 6MM, Diagnosed Prevalent Cases of Cushing's Disease, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 5: 6MM, Age-Specific Diagnosed Prevalent Cases of Cushing's Disease, Both Sexes, N, 2013
  • Figure 6: 6MM, Sex-Specific Diagnosed Prevalent Cases of Cushing's Disease, Ages ≥18 Years, N, 2013
  • Figure 7: 6MM, Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 8: 6MM, Age-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Both Sexes, N, 2013
  • Figure 9: 6MM, Sex-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ≥18 Years, N, 2013
  • Figure 10: 6MM, Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 11: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Both Sexes, N, 2013
  • Figure 12: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ≥18 Years, N, 2013
  • Figure 13: 6MM, Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 14: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Both Sexes, N, 2013
  • Figure 15: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ≥18 Years, N, 2013
  • Figure 16: 6MM, Age-Standardized Diagnosed Prevalence of CS (%), Ages ≥18 Years, 2013
  • Figure 17: 6MM, Age-Standardized Diagnosed Prevalence of Cushing's Disease (%), Ages ≥18 Years, 2013
Back to Top